+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chronic Inflammatory Demyelinating Polyneuropathy Market by Treatment Modality, End User, Distribution Channel, Patient Age, Disease Severity - Global Forecast to 2030- Product Image
Chronic Inflammatory Demyelinating Polyneuropathy Market by Treatment Modality, End User, Distribution Channel, Patient Age, Disease Severity - Global Forecast to 2030- Product Image
Sale

Chronic Inflammatory Demyelinating Polyneuropathy Market by Treatment Modality, End User, Distribution Channel, Patient Age, Disease Severity - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967535
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Chronic Inflammatory Demyelinating Polyneuropathy Market grew from USD 2.49 billion in 2024 to USD 2.64 billion in 2025. It is expected to continue growing at a CAGR of 5.83%, reaching USD 3.50 billion by 2030.

Understanding Chronic Inflammatory Demyelinating Polyneuropathy and Market Imperatives

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) represents a formidable challenge in neuromuscular disorders, characterized by progressive weakness, sensory loss, and variable clinical presentations. As the global healthcare community grapples with diagnosis complexities and evolving therapeutic standards, stakeholders demand a sophisticated understanding of market dynamics and patient journeys. Rigorous research has unveiled critical factors driving innovation, including advances in immunological insights, patient stratification techniques, and enhanced delivery mechanisms for biologic therapies. This executive summary synthesizes these threads to equip decision-makers with a cohesive narrative on unmet needs, emerging therapies, and regulatory landscapes.

By illuminating current barriers to optimal care, such as delayed diagnosis and reimbursement hurdles, we lay the groundwork for strategic initiatives. The synthesis of primary and secondary research underscores the importance of multidisciplinary collaborations spanning neurology, immunology, and patient advocacy groups. Furthermore, the introduction sets the scene for subsequent exploration of transformative market shifts, policy impacts, segmentation nuances, regional differentiators, and competitive intelligence. It is designed to provide a compelling starting point for executives, investors, and clinicians seeking to navigate the intricacies of the CIDP market with precision and foresight.

Emerging Innovations and Policy Shifts Redefining Treatment Pathways

Over the past decade, the CIDP landscape has undergone transformative shifts propelled by breakthroughs in immunomodulatory therapies and evolving reimbursement frameworks. The introduction of novel monoclonal antibodies and biosimilars has disrupted traditional reliance on corticosteroids and plasma exchange, while digital health platforms enable remote monitoring of disease progression. Concurrently, regulatory bodies have updated clinical guidelines to reflect emerging evidence, fostering faster approval pathways for treatments addressing refractory cases. These innovations have widened the therapeutic arsenal but have also intensified competition among pharmaceutical and biotech firms.

Policy reforms aimed at containing healthcare costs have spurred value-based pricing negotiations, compelling manufacturers to demonstrate clear clinical and economic benefits. Real-world evidence generated through patient registries and electronic health records is increasingly informing coverage decisions, reshaping payer engagement. As the market pivots toward personalized medicine, advancements in biomarker discovery are unveiling new targets for intervention, underscoring the shift from one-size-fits-all approaches to precision medicine. This dynamic interplay between science, policy, and patient-centric care is redefining CIDP management, setting the stage for accelerated growth and differentiation in the years ahead.

Navigating the Implications of US Tariff Changes on Supply Chains

The implementation of United States tariffs in 2025 has reverberated across the CIDP therapeutic supply chain, creating ripple effects from raw material sourcing to finished product distribution. Increased duties on key biologic components and pharmaceutical-grade solvents elevated production costs, compelling manufacturers to reassess supplier agreements and inventory strategies. In response, many players have diversified their procurement networks to include lower-cost regions, while others have invested in localized manufacturing facilities to mitigate tariff exposure and ensure continuity of supply.

Healthcare providers and distribution partners have felt the impact through adjustments in pricing structures and contract negotiations. Some hospital systems have shifted toward long-term purchasing agreements to lock in favorable rates, while specialty clinics have explored alternative formulations and compounding services to manage budget constraints. Payers, mindful of escalating treatment expenses, have tightened formulary placement criteria and introduced outcomes-based contracting models. Although patients have experienced modest price increases, stakeholder collaboration has helped preserve access to essential therapies. As the market adapts, the tariff-induced realignment underscores the need for agile supply chain strategies and proactive stakeholder engagement.

Decoding Market Segments to Uncover Growth Drivers

Insight into the CIDP market reveals a tapestry of treatment options anchored by corticosteroids, immunosuppressants, intravenous and subcutaneous immunoglobulins, as well as plasma exchange therapies. Within immunosuppressants, the landscape further fragments into agents such as azathioprine, cyclophosphamide, mycophenolate mofetil and rituximab, each addressing distinct clinical scenarios from induction of remission to maintenance therapy. As clinicians tailor regimens to patient profiles, home care settings have emerged as a viable alternative to hospital-based administration, complemented by specialty clinics that offer targeted infusion services.

Distribution channels also play a pivotal role in shaping access, with hospital pharmacies often serving as hubs for inpatient treatments, while online and retail pharmacies cater to outpatient and home-managed therapies. Age-wise, adult patients represent the core demographic, but cohort studies highlight a growing geriatric population with comorbidities and a smaller pediatric segment requiring weight-based dosing adaptations. Disease severity segmentation-ranging from mild to severe presentations-guides therapeutic intensity and frequency, driving demand for treatments that balance efficacy with safety. Together, these segmentation insights elucidate growth pockets and inform strategic positioning for stakeholders across the value chain.

Regional Variations Shaping Demand and Access Patterns

The Americas continue to dominate CIDP market activity, driven by robust healthcare infrastructure, high patient awareness and favorable reimbursement policies. In this region, innovations in telemedicine have streamlined diagnosis and management pathways, while a dense network of specialty clinics accelerates clinical trial enrollment. Conversely, Europe, the Middle East & Africa exhibit heterogeneous adoption rates, with Western Europe embracing advanced therapies more rapidly than emerging markets, where budget constraints and variable regulatory environments temper uptake. Stakeholders often engage in public-private partnerships to enhance access, particularly in regions seeking to expand neuromuscular disease programs.

Across Asia-Pacific, rising healthcare investments and growing patient populations are fueling demand for cost-effective treatment options. Governments in several countries are revising national formularies to include essential immunoglobulin therapies, stimulating local production and licensing agreements. Despite disparities in infrastructure and regulatory maturity, the region’s trajectory points toward accelerated adoption of both originator biologics and biosimilars. Recognizing these regional nuances is critical for manufacturers planning market entry or expansion, as tailored strategies are essential to navigate diverse payer landscapes and patient access challenges.

Competitive Landscape Highlights Major Industry Players

The competitive landscape in the CIDP market features a blend of established pharmaceutical giants and emerging biotech innovators. Leading players have leveraged their global distribution networks to introduce next-generation immunoglobulin formulations and targeted biologics, often backed by expansive clinical trial programs. Meanwhile, agile newcomers are focusing on niche segments, such as subcutaneous delivery methods or combination therapies that promise improved patient convenience and adherence.

Strategic alliances and licensing agreements have become commonplace as companies seek to accelerate time-to-market and share development risks. Some entities have diversified their portfolios to include biomarkers and diagnostic assays, enabling them to offer end-to-end solutions for CIDP management. Meanwhile, investment in manufacturing capacity and supply chain resilience remains a priority, especially in the wake of recent tariff-driven disruptions. Through continuous innovation, strategic collaborations and an emphasis on patient-centric care models, leading companies are positioning themselves to capture evolving opportunities in this high-growth therapeutic domain.

Strategic Imperatives to Capitalize on Emerging Opportunities

Industry leaders should prioritize partnerships that integrate advanced diagnostics with therapeutic development to create precision care models. Investing in digital health platforms capable of tracking real-world treatment outcomes will not only support value-based contracting but also generate evidence for payer negotiations. Additionally, enhancing supply chain resilience through regional manufacturing hubs and diversified procurement strategies will mitigate the impact of trade policy fluctuations and raw material shortages.

To foster sustainable growth, companies must adopt patient engagement initiatives that extend beyond clinical settings, incorporating caregiver education and telehealth services. Early and proactive collaboration with regulatory authorities can streamline approval pathways for novel therapies, while alliances with academic centers and advocacy groups will amplify research efforts. Finally, portfolio diversification-through acquisition of complementary assets or in-licensing of promising biologics-can bolster market position and hedge against pricing pressures. By aligning on these strategic imperatives, industry stakeholders can unlock new value and elevate standards of care for patients with CIDP.

Rigorous Methodology Underpinning Our Market Analysis

This analysis is grounded in a rigorous research methodology that integrates both primary and secondary data sources. In-depth interviews were conducted with leading neurologists, payers, industry executives and patient advocacy representatives to capture firsthand perspectives on clinical practice patterns, reimbursement frameworks and therapeutic preferences. Secondary research encompassed a comprehensive review of peer-reviewed journals, regulatory filings, company reports and global clinical trial registries.

Quantitative data was synthesized to identify key trends in treatment adoption, pricing dynamics and supply chain movements, while qualitative insights enriched the contextual understanding of stakeholder motivations. Robust triangulation techniques were employed to validate findings, ensuring the reliability and relevance of conclusions drawn. To accommodate the complex nature of the CIDP market, the study also incorporated scenario analyses reflecting policy shifts such as the 2025 tariff adjustments. This methodological rigor underpins the actionable insights and strategic recommendations outlined throughout this summary.

Synthesis of Insights and Pathways Forward

The synthesis of findings reveals a rapidly evolving CIDP landscape shaped by therapeutic innovation, policy transformations and geopolitical factors. Treatment paradigms are shifting toward precision medicine, with emerging biologics and biosimilars challenging legacy therapies. Supply chain adaptability has become paramount in the face of tariff-induced cost pressures, prompting regional localization and strategic partnerships. Detailed segmentation analysis highlights distinct growth pockets across treatment modalities, end users, patient demographics and disease severity.

Regional disparities underscore the importance of bespoke market entry and expansion strategies, tailored to the unique payer environments of the Americas, Europe, Middle East & Africa, and Asia-Pacific. The competitive milieu features a dynamic mix of incumbents and disruptors, driving continuous differentiation through clinical trials, licensing agreements and supply chain innovations. Collectively, these insights chart a pathway for stakeholders to navigate complexity, seize emerging opportunities and deliver enhanced patient outcomes. As the market continues to mature, agile strategies and collaborative ecosystems will be critical for sustaining leadership in CIDP care.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Modality
    • Corticosteroids
    • Immunosuppressants
      • Azathioprine
      • Cyclophosphamide
      • Mycophenolate Mofetil
      • Rituximab
    • Intravenous Immunoglobulin
    • Plasma Exchange
    • Subcutaneous Immunoglobulin
  • End User
    • Home Care
    • Hospitals
    • Specialty Clinics
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Patient Age
    • Adult
    • Geriatric
    • Pediatric
  • Disease Severity
    • Mild
    • Moderate
    • Severe
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Grifols, S.A.
  • CSL Behring AG
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
  • Baxter International Inc.
  • LFB S.A.
  • Kedrion S.p.A.
  • Biotest AG
  • Kamada Ltd.
  • Shanghai RAAS Blood Products Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment Modality
8.1. Introduction
8.2. Corticosteroids
8.3. Immunosuppressants
8.3.1. Azathioprine
8.3.2. Cyclophosphamide
8.3.3. Mycophenolate Mofetil
8.3.4. Rituximab
8.4. Intravenous Immunoglobulin
8.5. Plasma Exchange
8.6. Subcutaneous Immunoglobulin
9. Chronic Inflammatory Demyelinating Polyneuropathy Market, by End User
9.1. Introduction
9.2. Home Care
9.3. Hospitals
9.4. Specialty Clinics
10. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Patient Age
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Disease Severity
12.1. Introduction
12.2. Mild
12.3. Moderate
12.4. Severe
13. Americas Chronic Inflammatory Demyelinating Polyneuropathy Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Grifols, S.A.
16.3.2. CSL Behring AG
16.3.3. Octapharma AG
16.3.4. Takeda Pharmaceutical Company Limited
16.3.5. Baxter International Inc.
16.3.6. LFB S.A.
16.3.7. Kedrion S.p.A.
16.3.8. Biotest AG
16.3.9. Kamada Ltd.
16.3.10. Shanghai RAAS Blood Products Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET MULTI-CURRENCY
FIGURE 2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET MULTI-LANGUAGE
FIGURE 3. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 47. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 48. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 49. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 52. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 53. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 54. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 55. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 58. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 79. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 80. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 83. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 84. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 85. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 86. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 89. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 90. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 91. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 92. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 95. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 96. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 97. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 98. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 101. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 102. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 103. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 104. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 107. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 108. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 109. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 110. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 113. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 114. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 115. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 116. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 119. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 131. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 132. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 133. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 134. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 137. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 143. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 144. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 145. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 146. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 149. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 150. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 151. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 152. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 155. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 156. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 157. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 158. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 161. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 162. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 163. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 164. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 167. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 168. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 169. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 170. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 173. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 174. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 175. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 176. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 179. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 180. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 186. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 187. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 188. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 191. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 192. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 193. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 194. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 197. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 198. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 199. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 200. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 203. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 211. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 212. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 213. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 216. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 217. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 218. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 219. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 222. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 223. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 224. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 225. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 228. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 235. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 236. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 247. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 248. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 249. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 252. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 253. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 254. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 255. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 258. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING P

Companies Mentioned

The companies profiled in this Chronic Inflammatory Demyelinating Polyneuropathy market report include:
  • Grifols, S.A.
  • CSL Behring AG
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
  • Baxter International Inc.
  • LFB S.A.
  • Kedrion S.p.A.
  • Biotest AG
  • Kamada Ltd.
  • Shanghai RAAS Blood Products Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages191
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.64 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.5 Billion
Compound Annual Growth Rate5.8%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Global Clinical Trials Review, 2024 - Product Image

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Global Clinical Trials Review, 2024

  • Clinical Trials
  • 102 Pages
  • Global
From
2025 Global Forecast for Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) Market (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) Market (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Market Report 2025 - Product Image

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pipeline Insight, 2025 - Product Image

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Market

The CIDP Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. CIDP Drugs are used to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder that affects the peripheral nervous system. CIDP Drugs are typically immunomodulatory agents, such as corticosteroids, intravenous immunoglobulin (IVIg), and plasma exchange. These drugs are used to reduce inflammation and improve nerve conduction. The CIDP Drug market is highly competitive, with several major players. Companies such as Pfizer, Merck, and Novartis are leading the market with their immunomodulatory agents. Other companies such as Biogen, Sanofi, and AbbVie are also active in the CIDP Drug market, offering a range of treatments for CIDP. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.